Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Eckardt, K.-U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eckardt, K.-U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1745-1749
© 2001 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

After 15 years of success—perspectives of erythropoietin therapy

Kai-Uwe Eckardt

Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow-Klinikum, Berlin, Germany

Keywords: erythropoietin therapy

Introduction

In 1985, the human erythropoietin (Epo) gene was cloned, based on limited structural information derived from a few milligrams of the hormone that were isolated from a large amount of urine. No more than two years later, the first reports about the successful correction of renal anaemia with recombinant human (rh) Epo were published. Since then, rhEpo has become (i) a standard treatment for dialysis patients, (ii) an interesting therapeutic option for several forms of non-renal anaemia and (iii), as a consequence of both, the drug with the highest annual sales worldwide. Considering this process, one might assume that we have passed the summit and that most of the excitement associated with the discovery and therapeutic application of this hormone lies in the past. On the other hand, it is this success that has set the stage for an ongoing story. Several very interesting developments regarding the ‘when’ and ‘how’ . . . [Full Text of this Article]

Renal anaemia

Non-renal indications

Heart failure
Critical illness
Brain injury
Novel treatment approaches

Gene activated Epo (gaEpo)
Novel erythropoiesis-stimulating protein (NESP)
Epo-mimetics and modulation of receptor activity
Epo gene therapy
Conclusions

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?